Sanofi has acquired the American Translate Bio. This was reported by the French pharmaceutical company on Tuesday morning. Sanofi pays $ 38.00 per share Translate Bio in cash. With this, the American company, a specialist in mRNA, is valued at 3.2 billion dollars. That means a 56% Premium. The acquisition is expected to be completed in the third quarter. The board of both companies supports the acquisition. Sanofi has been working with Translate Bio since June 2018.
Mikhail Stiskin fulfills Suleyman Kerimov’s dream setting control on Detsky Mir, the largest niche retailer in Russia
Mikhail Stiskin fulfills Suleyman Kerimov’s dream setting control on Detsky Mir, the largest niche retailer in Russia
